Breaking News Instant updates and real-time market news.

UAA

Under Armour

$21.94

0.14 (0.64%)

, UA

Under Armour

$19.66

0.19 (0.98%)

06:10
04/18/19
04/18
06:10
04/18/19
06:10

Under Armour Q1 expectations 'at least achievable,' says Piper Jaffray

Piper Jaffray analyst Erinn Murphy says her work year-to-date indicates generally well controlled inventory across the domestic athletic industry. Currently, Under Armour (UAA) online clearance styles are down 19% year-over-year versus Nike's (NKE) down 5% and Adidas' (ADDYY) up 96%. The analyst believes industry competition "should remain rational" during 2019. Further, Q1 consensus expectations for Under Armour are "at least achievable" and management should maintain fiscal 2019 guidance, Murphy tells investors in a pre-earnings research note. The analyst this quarter has seen on-going traction with HOVR's footwear platform, broader focus with Under Armour's women's and a well-supported launch of Rush. She keeps an Overweight rating on Under Armour shares with a $30 price target.

UAA

Under Armour

$21.94

0.14 (0.64%)

UA

Under Armour

$19.66

0.19 (0.98%)

NKE

Nike

$88.74

0.84 (0.96%)

ADDYY

Adidas

$0.00

(0.00%)

  • 09

    May

  • 09

    May

UAA Under Armour
$21.94

0.14 (0.64%)

04/12/19
JEFF
04/12/19
NO CHANGE
JEFF
Under Armour discounts flat to down for 12th straight month, says Jefferies
Jefferies analyst Randal Konik says his firm's March webscrapes illustrate that Under Armour's (UAA) percentage of product on discount is flat to down for the twelfth month in a row year-over-year, Jefferies analyst Randal Konik tells investors in a research note. Further, the webscrapes show Adidas's (ADDYY) percentage of product on discount is up for the twelfth month in a row year-over-year, adds the analyst. In addition, visits to Finish Line (FINL), Foot Locker (FL), and Under Armour websites reveal the HOVR, Project Rock, and Curry 6 are sold out in several sizes, indicating strong demand, says Konik. He believes Nike (NKE) continues to dominate Adidas in running in the U.S., with strength in Air VaporMax and Air Max 270. The analyst also thinks the data bodes well for Under Armour's's sales and margins in Q1.
04/10/19
04/10/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. First Solar (FSLR) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Brian Lee citing his view on two potential company-specific catalysts. 2. Disney (DIS) upgraded to Outperform from Market Perform at BMO Capital with analyst Daniel Salmon saying with tomorrow's investor day, two Star Wars-themed lands opening in the domestic parks this summer, the launch of streaming service Disney+ before year-end, and a potential re-start of the buyback program within 12 months, Disney shares now have catalysts to go along with downside protection. 3. Under Armour (UA, UAA) assumed with a Buy from Neutral at Citi with analyst Paul Lejuez saying Under Armour is "growing up" with a renewed focus on driving profitability and return on invested capital. 4. KB Home (KBH) upgraded to Neutral from Underweight at JPMorgan with analyst Michael Rehaut saying the ongoing shift towards smaller-sized first-time product and double-digit community count growth should drive "above average fundamentals" in fiscal 2019 for KB Home. 5. Nordstrom (JWN) upgraded to Overweight from Sector Weight at KeyBanc with analyst Edward Yruma saying recent meetings with co-CEO Erik Nordstrom and CFO Anne Bramman affirm that the company is prepared to transition its asset base as e-commerce continues to grow. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/10/19
SBSH
04/10/19
UPGRADE
Target $29
SBSH
Buy
Under Armour assumed with a Buy from Neutral at Citi
Citi analyst Paul Lejuez assumed coverage of Under Armour (UAA) from Kate McShane and upgraded the shares to Buy from Neutral. He raised his price target for the stock to $29 from $23. Under Armour is "growing up" with a renewed focus on driving profitability and return on invested capital, Lejuez tells investors in a research note. With just a 3.4% EBIT margin in 2018, the company has the opportunity to recapture 600 basis points in EBIT margin over the next several years, says the analyst. And near-term, Lejuez sees upside to management's fiscal 2019 gross margin guidance.
04/09/19
RILY
04/09/19
NO CHANGE
RILY
Under Armour continues to lag behind competitors, says B. Riley FBR
B. Riley FBR analyst Susan Anderson says her firm's annual athletic footwear/apparel survey showed that Under Armour (UAA) continues to lag behind competitors across basketball, running, and casual footwear and athletic apparel. Respondents placed Under Armour behind brands such as New Balance and Puma, in addition to Nike (NKE) and Adidas (ADDYY), which maintained the number one and two spots in this year's survey, Anderson tells investors in a research note. She keeps a Sell rating on Under Armour with a $12 price target.
UA Under Armour
$19.66

0.19 (0.98%)

NKE Nike
$88.74

0.84 (0.96%)

04/10/19
SBSH
04/10/19
DOWNGRADE
Target $68
SBSH
Neutral
Foot Locker assumed with a Neutral from Buy at Citi
Citi analyst Paul Lejuez assumed coverage of Foot Locker (FL) from Kate McShane and downgraded the shares to Neutral from Buy. He also lowered his price target for the stock to $68 from $72. While Foot Locker has "tailwinds at its back" in North America with comps inflecting positively in Q4, the company still faces many of the same headwinds as other specialty retailers given its "significant" mall exposure and EBIT pressure from direct-to-consumer, Lejuez tells investors in a research note. He believes Nike's direct-to-consumer ambitions are a "secular headwind" for Foot Locker.
04/10/19
SBSH
04/10/19
INITIATION
Target $100
SBSH
Buy
Nike assumed with a Buy rating, $100 price target at Citi
Citi analyst Paul Lejuez assumed coverage of Nike from Kate McShane and kept a Buy rating on the shares. He raised his price target for the stock to $100 from $96. Nike is the dominant player in the global athletic footwear and apparel market, which is a "healthy and growing market buoyed by structural tailwinds," Lejuez tells investors in a research note.
ADDYY Adidas
$0.00

(0.00%)

03/14/19
MSCO
03/14/19
NO CHANGE
Target $103
MSCO
Overweight
Morgan Stanley sees Q3 EPS beat coming from Nike
Morgan Stanley analyst Lauren Cassel previewed Nike's (NKE) Q3 report, stating that she expects an EPS beat and a high-single digit constant currency revenue growth forecast for FY20 coming from the company. Adidas' (ADDYY) Q4 sales ex-Reebok were notably softer in North America on a constant currency basis, noted Cassel, who reads this as a sign that its share losses are accelerating. She maintains an Overweight rating and $103 price target on Nike ahead of the company's Q3 earnings report on Thursday, March 21.
02/25/19
02/25/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Norwegian Cruise Line (NCLH) upgraded to Outperform from Neutral at Macquarie. 2. Brunswick (BC) upgraded to Overweight from Neutral at JPMorgan by analyst Steven Zaccone, who said that following recent "encouraging" data points on the marine industry, macro backdrop, and company-specific growth drivers, the setup is more favorable to own Brunswick in 2019. 3. UGI Corporation (UGI) upgraded to Buy from Neutral at UBS by analyst Shneur Gershuni, who said the 8% selloff since mid-December is an overreaction to the company's recent Q1 miss on the back of warm weather. The analyst believes UGI's strategic review of AmeriGas (APU) could "substantially increase" the company's cash flow and market capitalization if a roll-up is the outcome.4. Infinera (INFN) upgraded to Neutral from Sell at MKM Partners by analyst Michael Genovese, who said the company's commentary about new bookings was better than he expected. Genovese also noted that management's view of significant backlog growth in Q4 and expectations for another increase in Q1, but warned that there is still "significant risk" to Infinera's 2019 revenue outlook being a "high hurdle." 5. Adidas (ADDYY) upgraded to Outperform from Market Perform at Wells Fargo by analyst Tom Nikic, who said his math suggests a greater-than-expected contribution from the long-awaited democratization of the Yeezy sub-brand. The company seems to have hit a ''lull'' on new product launches for the core brand and faces headwinds from the 2018 World Cup through Q2 of 2019, but Nikic believes these challenges are well understood by investors, and the ''opening the faucet'' on the Yeezy brand can get Adidas through these 2019 challenges and allow for a ''soft landing'' on the top line in 2019. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

UTX

United Technologies

$125.30

0.45 (0.36%)

, SNE

Sony

$51.42

1.735 (3.49%)

19:15
06/16/19
06/16
19:15
06/16/19
19:15
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

UTX

United Technologies

$125.30

0.45 (0.36%)

SNE

Sony

$51.42

1.735 (3.49%)

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

GS

Goldman Sachs

$191.71

0.24 (0.13%)

DB

Deutsche Bank

$6.79

-0.07 (-1.02%)

BA

Boeing

$347.19

-1.54 (-0.44%)

RTN

Raytheon

$177.38

0.195 (0.11%)

MCK

McKesson

$133.19

-1.7 (-1.26%)

CAH

Cardinal Health

$44.16

-1.13 (-2.50%)

ABC

AmerisourceBergen

$85.01

-1.46 (-1.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 17

    Jun

  • 23

    Jun

  • 25

    Jun

  • 27

    Jun

  • 09

    Jul

  • 10

    Jul

  • 16

    Jul

GM

General Motors

$35.66

-0.36 (-1.00%)

18:49
06/16/19
06/16
18:49
06/16/19
18:49
Periodicals
GM won't deploy self-driving fleet until safer than human driver, Axios reports »

General Motors CEO Mary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 12

    Aug

T

AT&T

$32.36

0.06 (0.19%)

, CMCSA

Comcast

$42.31

0.62 (1.49%)

17:58
06/16/19
06/16
17:58
06/16/19
17:58
On The Fly
Box Office Battle: 'Men in Black: International' wins weekend with just $28.5M »

Sony’s (SNE) "Men in…

T

AT&T

$32.36

0.06 (0.19%)

CMCSA

Comcast

$42.31

0.62 (1.49%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$51.42

1.735 (3.49%)

LGF.A

Lionsgate

$12.22

-0.85 (-6.50%)

DIS

Disney

$141.64

-0.09 (-0.06%)

VIAB

Viacom

$29.38

-0.28 (-0.94%)

VIA

Viacom

$34.61

0.14 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 24

    Jul

  • 25

    Jul

  • 08

    Aug

  • 08

    Aug

GS

Goldman Sachs

$191.71

0.24 (0.13%)

17:43
06/16/19
06/16
17:43
06/16/19
17:43
Periodicals
Goldman Sachs combining private-investing units, WSJ reports »

Goldman Sachs is pulling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 16

    Jul

DB

Deutsche Bank

$6.79

-0.07 (-1.02%)

17:38
06/16/19
06/16
17:38
06/16/19
17:38
Periodicals
Deutsche Bank to set up EUR50B bad bank, Financial Times reports »

Deutsche Bank is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$87.10

(0.00%)

16:35
06/16/19
06/16
16:35
06/16/19
16:35
Periodicals
Tires blow on United jet during Newark airport landing, Reuters reports »

Tires on a United…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$87.83

-0.48 (-0.54%)

16:33
06/16/19
06/16
16:33
06/16/19
16:33
Periodicals
Target registers back online after outage blamed on tech issue, Reuters says »

Target said its payment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$46.18

-0.54 (-1.16%)

16:30
06/16/19
06/16
16:30
06/16/19
16:30
Hot Stocks
Intel announces program for Israeli startups targeting tech inflections »

Intel announced a program…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 25

    Jul

BA

Boeing

$347.19

-1.54 (-0.44%)

16:27
06/16/19
06/16
16:27
06/16/19
16:27
Periodicals
Boeing says will take time to rebuild customer confidence, Reuters reports »

The head of Boeing said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 09

    Jul

GS

Goldman Sachs

$191.71

0.24 (0.13%)

16:19
06/16/19
06/16
16:19
06/16/19
16:19
Periodicals
Goldman Sachs skeptical of 'insurance' rate cuts from Fed, Reuters says »

Goldman Sachs economists…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 16

    Jul

BA

Boeing

$347.19

-1.54 (-0.44%)

16:16
06/16/19
06/16
16:16
06/16/19
16:16
Periodicals
Trials nearing for Boeing 737 Max fix, WSJ reports »

The Federal Aviation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 09

    Jul

ESLT

Elbit Systems

$154.55

0.55 (0.36%)

13:41
06/16/19
06/16
13:41
06/16/19
13:41
Hot Stocks
Elbit Systems awarded $50M contract »

Elbit Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$176.09

-0.74 (-0.42%)

13:40
06/16/19
06/16
13:40
06/16/19
13:40
Hot Stocks
Amgen announces BLINCYTO five-year overall survival data »

Amgen announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

SILK

Silk Road Medical

$44.80

-0.95 (-2.08%)

13:35
06/16/19
06/16
13:35
06/16/19
13:35
Hot Stocks
Silk Road Medical announces final results for ROADSTER-2 study »

Silk Road Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 26

    Aug

EDIT

Editas Medicine

$21.72

-0.78 (-3.47%)

13:30
06/16/19
06/16
13:30
06/16/19
13:30
Hot Stocks
Editas presents pre-clinical data in Sickle Cell Disease, Beta-Thalassemia »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNSS

Sunesis

$0.90

-0.055 (-5.79%)

13:28
06/16/19
06/16
13:28
06/16/19
13:28
Hot Stocks
Sunesis announces preliminary data from Phase 1b/2 trial of Vecabrutinib »

Sunesis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

APLS

Apellis

$21.22

-0.14 (-0.66%)

13:23
06/16/19
06/16
13:23
06/16/19
13:23
Hot Stocks
Apellis presents data from ongoing Phase 2 PLAUDIT study of APL-2 »

Apellis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

FTSV

Forty Seven

$10.55

-0.02 (-0.19%)

13:16
06/16/19
06/16
13:16
06/16/19
13:16
Hot Stocks
Forty Seven announces data from Phase 1b/2 trial of 5F9 in combo with Rituximab »

Forty Seven announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$39.68

-0.23 (-0.58%)

13:06
06/16/19
06/16
13:06
06/16/19
13:06
Hot Stocks
AstraZeneca announces results from interim analysis of Phase 2 ASCEND trial »

AstraZeneca announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

STRO

Sutro Biopharma

$11.17

-0.34 (-2.95%)

13:02
06/16/19
06/16
13:02
06/16/19
13:02
Hot Stocks
Sutro Biopharma announces interim Phase 1 safety data for STRO-001 »

Sutro Biopharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPMC

Blueprint Medicines

$90.65

-0.35 (-0.38%)

12:59
06/16/19
06/16
12:59
06/16/19
12:59
Hot Stocks
Blueprint Medicines presents updated EXPLORER trial data for Avapritinib »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

INCY

Incyte

$77.76

1.385 (1.81%)

12:52
06/16/19
06/16
12:52
06/16/19
12:52
Hot Stocks
Incyte announced results from Phase 2 study of Ruxolitinib cream in vitiligo »

Incyte announces 24-week…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

, INCY

Incyte

$77.76

1.385 (1.81%)

04:55
06/16/19
06/16
04:55
06/16/19
04:55
Conference/Events
European Hematology Association to hold a conference »

24th EHA Congress 2019…

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

INCY

Incyte

$77.76

1.385 (1.81%)

ARQL

ArQule

$8.17

1.88 (29.89%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

ALXN

Alexion

$117.94

0.65 (0.55%)

AGIO

Agios Pharmaceuticals

$47.97

-1.78 (-3.58%)

AZN

AstraZeneca

$39.68

-0.23 (-0.58%)

BLUE

Bluebird Bio

$117.57

-6.33 (-5.11%)

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

NSTG

NanoString

$25.96

0.45 (1.76%)

KPTI

Karyopharm

$5.71

-0.04 (-0.70%)

JAZZ

Jazz Pharmaceuticals

$130.43

0.28 (0.22%)

GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

GILD

Gilead

$66.38

-0.62 (-0.93%)

DSNKY

Daiichi Sankyo

$0.00

(0.00%)

PFE

Pfizer

$42.75

0.24 (0.56%)

PTLA

Portola Pharmaceuticals

$25.78

-0.31 (-1.19%)

QGEN

Qiagen

$39.52

-0.07 (-0.18%)

RHHBY

Roche

$0.00

(0.00%)

RIGL

Rigel Pharmaceuticals

$2.06

-0.06 (-2.83%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

SGEN

Seattle Genetics

$68.67

-0.33 (-0.48%)

STML

Stemline

$14.20

0.12 (0.85%)

VSTM

Verastem

$1.39

0.125 (9.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 18

    Jun

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 21

    Jun

  • 23

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 28

    Jun

  • 06

    Jul

  • 25

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 02

    Sep

  • 03

    Sep

  • 16

    Sep

  • 04

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

, GRUB

GrubHub

$70.15

-2.76 (-3.79%)

13:28
06/15/19
06/15
13:28
06/15/19
13:28
Periodicals
Amazon exit gives GrubHub stock boost, Barron's says »

Amazon (AMZN) is…

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 10

    Jul

ABC

AmerisourceBergen

$85.01

-1.46 (-1.69%)

, CAH

Cardinal Health

$44.16

-1.13 (-2.50%)

13:20
06/15/19
06/15
13:20
06/15/19
13:20
Periodicals
McKesson, Cardinal Health looking like bargains, Barron's says »

Investors have halved the…

ABC

AmerisourceBergen

$85.01

-1.46 (-1.69%)

CAH

Cardinal Health

$44.16

-1.13 (-2.50%)

MCK

McKesson

$133.19

-1.7 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.